Drug Profile
Tilarginine
Alternative Names: 546C88; ANO-1020; BW546C88; L-NMMA; N-Monomethyl-arginine; NMA; TAILatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Cornell Research Foundation; M. D. Anderson Cancer Center
- Developer Arginox Pharmaceuticals
- Class Antihypotensives; Basic amino acids; Diamino amino acids; Small molecules; Vascular disorder therapies
- Mechanism of Action Nitric oxide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Cardiogenic shock; Hypotension; Kidney disorders; Rheumatoid arthritis; Septic shock; Transplant rejection
Most Recent Events
- 17 Nov 2006 Discontinued - Phase-II for Hypotension in United Kingdom (unspecified route)
- 17 Nov 2006 Discontinued - Preclinical for Transplant rejection in Australia (unspecified route)
- 24 Aug 2006 Arginox Pharmaceuticals has terminated its phase III trial in cardiogenic shock in the US and Canada